Related Experiment Videos
Hematological side effects of co-trimoxazole
1Innere Medizin III, Zentrum für Innere Medizin, Ulm.
Abstract:
Decrease of blood cells may be induced by either components of co-trimoxazole. Side effects of the trimethoprim component are much more frequent, particularly in risk groups. They are dose dependent, usually not severe, only rarely of clinical significance and easily treated or prevented by folate supplementation. In contrast, side effects of the sulfamethoxazole component seem to be extremely rare. They are similar to the hematological side effects of other sulfonamide drugs. They are idiosyncratic, nonpredictable and mostly mediated by the immune-system. They may be of life-threatening severity and no therapy is known except termination of exposure and supportive measures such as substitution of blood cells and antiinfectious therapy by non-related antibiotics.
Insights
Co-trimoxazole can decrease blood cells, with trimethoprim causing more frequent, dose-dependent side effects manageable with folate. Sulfamethoxazole rarely causes severe, unpredictable immune-mediated blood cell issues requiring drug cessation.
Area of Science:
- Pharmacology
- Hematology
- Immunology
Background:
- Co-trimoxazole is a commonly prescribed antibiotic.
- Hematological side effects are a known concern with antibiotic use.
- Understanding the specific risks of each component is crucial for patient safety.
Purpose of the Study:
- To differentiate and describe the hematological side effects of trimethoprim and sulfamethoxazole, the components of co-trimoxazole.
- To assess the frequency, severity, and management strategies for these side effects.
Main Methods:
- Review of clinical data and literature on co-trimoxazole-induced hematological adverse events.
- Analysis of side effect profiles attributed to trimethoprim versus sulfamethoxazole.
- Comparison of management and prevention strategies.
Main Results:
- Trimethoprim-related side effects are more common, dose-dependent, and typically manageable with folate supplementation.
- Sulfamethoxazole-related side effects are rare, idiosyncratic, immune-mediated, and potentially severe.
- Management for sulfamethoxazole-induced effects involves drug discontinuation and supportive care.
Conclusions:
- The hematological risks associated with co-trimoxazole differ significantly between its components.
- Trimethoprim's effects are generally predictable and preventable, while sulfamethoxazole's are rare but serious.
- Clinical vigilance and appropriate management are essential when prescribing co-trimoxazole, especially in at-risk populations.